Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

NCT06751901 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Advanced NSCLC

Interventions

RADIATION: Radiotherapy
DRUG: PD-1 inhibitor
DRUG: Neoantigen-based peptide vaccine

Sponsor

The First Affiliated Hospital of Nanchang University